Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Weatherhead School’s Scott Shane discusses the heritability of entrepreneurial skill
- Spartan pitcher Robert Winemiller a potential MLB draft selection
- Weatherhead School study links boardroom team dynamics with profitability
- Law’s Ruqaiijah Yearby discusses racial disparities in health care
- Tri Sigma to join Case Western Reserve in Fall 2014